Medical Information
In order to provide you with relevant and meaningful content we need to know more about you.
Please choose the category that best describes you.
This content is intended for U.S. Healthcare Professionals. Would you like to proceed?
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Nalbuphine Hydrochloride Injection for intramuscular, subcutaneous, or intravenous use is a sterile solution available in:
| Unit of Sale | Concentration |
|---|---|
| NDC 0409-1463-01 | 10 mg/ mL |
| Tray of 10 – 1 mL Single-dose Ampuls | |
| NDC 0409-1465-01 | 20 mg/ mL |
| Tray of 10 – 1 mL Single-dose Ampuls | |
| NDC 0409-1464-01 | 100 mg/10 mL |
| Case of 25 – 10 mL Multiple-dose Fliptop Vials | (10 mg/ mL) |
| NDC 0409-1467-01 | 200 mg/10 mL |
| Case of 25 – 10 mL Multiple-dose Fliptop Vials | (20 mg/ mL) |
To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at